High-Quality Triptorelin CAS 57773-63-4 - China Suppliers and Factory of Sustained-Release GnRH Agonist Products Manufacturers, Pricelist
Triptorelin is a synthetic decapeptide and a potent gonadotropin-releasing hormone (GnRH) agonist, widely recognized for its ability to modulate hormone levels. By continuously activating pituitary GnRH receptors, Triptorelin initially stimulates the release of gonadotropins such as LH and FSH, followed by a decrease in their secretion, ultimately leading to lower levels of sex hormones like testosterone and estrogen. This product is commonly available in its acetate or papoate forms, with advanced sustained-release formulations such as 1, 3, or 6-month injections, making it ideal for ongoing treatment. As a leading player among China suppliers and factories, we ensure the highest quality Triptorelin to meet your medical and pharmaceutical needs
Triptorelin is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) agonist that works by acting continuously on pituitary GnRH receptors, initially stimulating and ultimately inhibiting the secretion of gonadotropins (LH, FSH), thereby reducing sex hormone (testosterone, estrogen) levels. Clinically, it is commonly used in acetate or pamoate form, with sustained-release formulations (such as 1, 3, or 6-month injections) to achieve continuous action.
Therapeutic Areas
🧬Oncology
Prostate cancer: First-line endocrine therapy for advanced, metastatic, or locally high-risk prostate cancer, inhibiting tumor growth by lowering testosterone to castration levels.
Breast cancer: Used for ovarian function suppression in premenopausal hormone receptor-positive breast cancer, in combination with other drugs to lower estrogen levels.
⚕️Gynecology & Reproductive Medicine
Endometriosis: Relieves pain and inhibits lesion progression.
Uterine fibroids: Preoperative reduction of fibroid size can decrease surgical difficulty and bleeding.
Central precocious puberty: Inhibits premature puberty development and improves adult height prognosis.
Assisted reproductive technology (ART): Used for pituitary downregulation before controlled ovarian hyperstimulation (COS).
🔬Other Fields
Sex-changing hormone therapy: As an initial treatment in the process of male-to-female transformation, it suppresses testosterone secretion.
Benign prostatic hyperplasia (BPH): Used for temporary relief of severe symptoms (the risk to bone health should be weighed for long-term use).
Outlook & Development
📈Market and Clinical Needs
The continued rise in the incidence of prostate and breast cancer, along with the demand for precision medicine in the field of reproductive health, supports the long-term market growth of Triptorelin.
Long-acting formulations (such as 6-month formulations) improve patient compliance and have become the current mainstream development direction.
💊Innovative Formulation and Delivery Systems
Sustained-release technologies: Such as microspheres and implants extend the dosing interval and reduce adverse reactions at the injection site.
Combination therapy: Combined with novel endocrine drugs (such as androgen receptor antagonists) or targeted drugs to enhance anti-tumor effects.
🎯Expanding Indications & Individualized Treatment
Explore its potential applications in ovarian cancer and pituitary hormone-related diseases.
By screening for individuals with specific health benefits through genetic testing or biomarkers, treatment strategies can be optimized.
💲Generic Drugs and Cost Control
After patents expire, competition from generic drugs intensifies, driving down healthcare system costs and improving drug accessibility.
Penetration in emerging markets (such as Asia and Latin America) further expands patient coverage.
🛡️Challenges and Responses
Side effect management: Such as decreased bone density, hot flashes, cardiovascular risks, etc., require enhanced monitoring and the development of mitigation strategies (such as combined osteoprotective agents).
Drug resistance issue: Some prostate cancer patients eventually progress to castration-resistant prostate cancer (CRPC), requiring exploration of sequential or combination therapies.
Frequently Asked Questions (FAQ)
QWhat is Triptorelin and how does it work?
Triptorelin is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) agonist. It acts continuously on pituitary GnRH receptors, which initially stimulates and ultimately inhibits the secretion of gonadotropins (LH, FSH), effectively reducing sex hormone levels such as testosterone and estrogen.
QWhat are the primary applications of Triptorelin in Oncology?
In Oncology, Triptorelin is primarily used as a first-line endocrine therapy for advanced or high-risk prostate cancer to lower testosterone to castration levels. It is also used in premenopausal hormone receptor-positive breast cancer to suppress ovarian function.
QHow is Triptorelin utilized in Gynecology and Reproductive Medicine?
It is utilized to relieve pain in endometriosis, reduce uterine fibroid size prior to surgery, inhibit central precocious puberty development, and for pituitary downregulation in assisted reproductive technology (ART).
QWhat is the mainstream development direction for Triptorelin formulations?
The current mainstream development focuses on long-acting formulations (such as 1, 3, or 6-month injections) and sustained-release technologies like microspheres and implants. These innovations aim to improve patient compliance and reduce adverse reactions.
QWhat are the main challenges associated with Triptorelin therapy?
The main challenges include managing side effects like decreased bone density, hot flashes, and cardiovascular risks. Additionally, managing drug resistance is a challenge, particularly when prostate cancer progresses to castration-resistant prostate cancer (CRPC).
Thin
